Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review

• Published in: Lupus Vol. 33; no. 4; pp. 414 - 419
• Main Authors: Fan, Qiuyu, Ji, Hongyan, Liu, Ya, Jia, Chao, Zou, Liang, Yang, Huiqin
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.04.2024; Sage Publications Ltd
• Subjects: Antibodies, Monoclonal, Humanized; APRIL protein; BLyS protein; Case reports; Clinical trials; Corticosteroids; Hepatitis; Hepatitis - drug therapy; Humans; Immunomodulation; Immunosuppressive Agents - therapeutic use; Inflammation; Literature reviews; Lupus; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - drug therapy; Lymphocytes B; Nonsteroidal anti-inflammatory drugs; Prospective Studies; Recombinant Fusion Proteins; Systemic lupus erythematosus; Treatment Outcome; case report; Systemic lupus erythematosus; lupus hepatitis; belimumab; telitacicept
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/09612033241233021

Background: Systemic lupus erythematosus (SLE)–associated hepatitis (“lupus hepatitis”) was one of the most frequent causes of liver function abnormalities in patients with SLE. Lupus hepatitis (LH) is commonly treated with conventional treatment, including non-steroidal anti-inflammatory drugs, corticosteroids, and immunomodulators. However, in refractory cases, other treatment options may be required. Methodology: We report the case of a patient with lupus hepatitis refractory to both conventional therapy and belimumab who was successfully treated with telitacicept, a new dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor.Literature review was performed on PubMed search forum. Result: The specific search term was “telitacicept”, 23 papers were searched, among them 10 case reports/series articles reporting telitacicept treatment were elected.Apart from our literature reporting the effectiveness of telitacicept in treating LH, there is no report on it in treating LH. Conclusion: This case suggests that telitacicept should be an effective and safe treatment for LH refractory, even to those who failed to belimumab based on the standard treatment, and can reduce the dosage of glucocorticoids.However, further investigations, particularly prospective randomized controlled trials, are warranted to verify our findings and ensure patient safety.